Completed PHASE1 INTERVENTIONAL 2-arm NCT01467518

Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.

A Phase 1, Open-Label, 2-Period Drug Interaction Study to Assess Steady State Plasma Methadone Enantiomer Pharmacokinetics Following Co-Administration of Methadone QD With Dolutegravir (GSK1349572) 50 mg Twice Daily in Opiate-Dependent, HIV Seronegative Adult Subjects.

Sponsor: GlaxoSmithKline

Conditions Infections, Human Immunodeficiency Virus and Hepatitis

Interventions Dolutegravir Methadone

Updated 5 times since 2017 Last updated: Apr 5, 2012 Started: Dec 31, 2011 Primary completion: Feb 29, 2012 Completion: Feb 29, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01467518, this PHASE1 trial focuses on Infections, Human Immunodeficiency Virus and Hepatitis and remains completed. Sponsored by GlaxoSmithKline, it has been updated 5 times since 2011, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Shionogi
ViiV Healthcare

Data source: ViiV Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada